Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE as a Surrogate
Status: Recruiting
Location: See location...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Candidates for 177Lu-DOTATATE (Lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor
Locations
United States
Wisconsin
University of Wisconsin - Madison
RECRUITING
Madison
Contact Information
Primary
Radiology Studies
Radstudy@uwhealth.org
608-282-8349
Time Frame
Start Date: 2025-03-07
Estimated Completion Date: 2026-02
Participants
Target number of participants: 10
Treatments
Experimental: Participants treated with Lutathera
Related Therapeutic Areas
Sponsors
Leads: University of Wisconsin, Madison